SHAGORY PETER K 4/A

What Happened

• Peter K. Shagory, EVP, Strategy & Corporate Development of CONMED Corporation (CNMD), was granted 16,926 restricted stock units (RSUs) on 2026-03-02. The RSUs were reported as a derivative award (grant) at $0.00 per share (no cash paid at grant).
• RSUs represent a contingent right to receive one share of CONMED common stock upon vesting; the award will generally vest 33% after one year, 33% after two years, and 34% after three years under the Company’s 2025 Long-Term Incentive Plan.

Key Details

• Transaction date: 2026-03-02; Form 4/A filed: 2026-03-18 (amended filing).
• Grant: 16,926 RSUs @ $0.00 (derivative award). Original filing reported 9,282 RSUs; this amendment adds a special award of 7,644 RSUs for a corrected total of 16,926 (footnote).
• Shares owned after transaction: not disclosed in the information provided in this summary.
• Footnote highlights: RSUs vest over three years (33% / 33% / 34%) under the 2025 LTIP. This Form 4/A was filed to correct the amount of RSUs granted.
• Timeliness: The amendment was filed 16 days after the transaction date, which is outside the standard two-business-day window for initial Form 4 reporting; amended filings to correct errors are common but late filings can raise compliance questions.

Context

• This is a compensation grant (award), not a market purchase or sale, so it reflects company compensation practices rather than an immediate insider bet on the stock.
• For retail investors, grants are informative about executive compensation and retention incentives but do not by themselves indicate intent to buy or sell shares on the open market.